Three-month follow-up of pulmonary embolism in patients with COVID-19.
Julia Czuprynska , Raj K Patel , Michael Waller , Martin B Whyte
Thrombosis Research 201 113 -115
2021
Influence of Antiplatelet and Anticoagulant Drug Use on Outcomes after Chronic Subdural Hematoma Drainage.
Michael T.C. Poon , Catherine Rea , Angelos G. Kolias , Paul M. Brennan
Journal of Neurotrauma 38 ( 8) 1177 -1184
10
2021
Postdischarge venous thromboembolism following hospital admission with COVID-19.
Lara N. Roberts , Martin B. Whyte , Loizos Georgiou , Gerard Giron
Blood 136 ( 11) 1347 -1350
200
2020
Fibrinogen as a hemostatic agent.
Benny Sørensen , Ole Larsen , Catherine Rea , Mariann Tang
Seminars in Thrombosis and Hemostasis 38 ( 3) 268 -273
51
2012
Fibrinogen concentrate and cryoprecipitate but not fresh frozen plasma correct low fibrinogen concentrations following in vitro haemodilution
Christian Fenger-Eriksen , Kirsten Christiansen , John Laurie , Benny Sørensen
Thrombosis Research 131 ( 5) e210 -e213
16
2013
Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic.
Rachna Patel , Julia Czuprynska , Lara N. Roberts , Bipin Vadher
Thrombosis Research 197 192 -194
1
2021
Reducing vascular risk – venous thromboembolism and anticoagulation:
Catherine Rea , Beverley J Hunt
Clinical Risk 15 ( 3) 90 -92
2009
Thrombocytopenia in the Newborn
Robert Carr , Timothy Watts , Catherine Rea
Springer, Cham 825 -840
2017
Rivaroxaban for the treatment of superficial vein thrombosis, experience at King’s College Hospital
Rachel E Clapham , Victoria Speed , Julia Czuprynska , Anna Gazes
British Journal of Haematology 196 ( 1) e3 -e6
5
2022
FULL TITLE
Michael TC Poon , Catherine Rea , Angelos G Kolias , Paul M Brennan
Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A
C. J. REA , J. H. FOLEY , J. INGERSLEV , B. SØRENSEN
Journal of Thrombosis and Haemostasis 9 ( 3) 510 -516
22
2011
Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
C. REA , A. DUNKERLEY , B. SØRENSEN , S. RANGARAJAN
Haemophilia 15 ( 6) 1237 -1242
15
2009
The TFPI antibody, Concizumab, improves thrombin generation in plasma from patients with hemophilia A, hemophilia B or inhibitors
EMILY WATERS , Ida Hilden , Supreet Dhillon , CATHERINE REA
Haemophilia 20 82 -83
1
2014
Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
A Tiede , B Brand , R Fischer , K Kavakli
Journal of Thrombosis and Haemostasis 11 ( 4) 670 -678
165
2013
Monitoring direct oral anticoagulant plasma concentrations-experience from the Princess Royal University Hospital
R Patel , E Yellen , J Patel , R Arya
BRITISH JOURNAL OF HAEMATOLOGY 189 275 -276
2020
Tinzaparin thromboprophylaxis for prosthetic valves in pregnancy: PP-MO-371
C Rea , S Rangarajan , B Hunt
Journal of Thrombosis and Haemostasis 7
2009
rFVIIa-analogue and rFVIIa enhance clot stability more than FVIII in haemophilia A: P-TU-503
C Rea , M Ezban , J Foley , B Sorensen
Journal of Thrombosis and Haemostasis 9
4
2011
Enhancing the pharmacokinetic properties of recombinant factor VIII: A first human dose trial with GlycoPEGylated recombinant factor VIII in patients with hemophilia A: FP-MO-03.2-2
A Tiede , B Brand , R Fisher , K Kavakli
Haemophilia 18
1
2012
Solulin increases clot stability in whole blood from individuals with hemophilia A or B: O-TU-077
J Foley , C Rea , K Petersen , M Nesheim
Journal of Thrombosis and Haemostasis 9
1
2011
Identifying tools to track hypercoagulability in COVID-19 Patients. Exploring Global Haemostasis (ROTEM) andneutrophil Extracellular Traps (NETS) Immunoassays
S Stanford , C Rea , A Roy , B Harris
Research and Practice in Thrombosis and Haemostasis
2021